NCT00244985View on ClinicalTrials.gov

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

December 31, 2012

Conditions

Lymphoma

Interventions

BIOLOGICAL

rituximab

IV

DRUG

pegylated liposomal doxorubicin hydrochloride

IV

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Ortho Biotech, Inc.

All Listed Sponsors

collaborator

Ortho Biotech, Inc.

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT00244985 - Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter